Project: Developing a molecular predictive assay to optimise riTUXImab therapy in Rheumatoid Arthritis
We discovered that the level of type I interferon response gene expression (the so-called IFN signature) predicts rituximab (RTX) therapy response in Rheumatoid Arthritis (RA) patients. The TUXIRA consortium is designed to develop an innovative molecular diagnostic based on this patented genomic profile. The main result of TUXIRA is the PreselectSCAN: a RT-PCR test together with a dedicated IT platform for data analysis to identify RA RTX non-responders with high sensitivity and specificity.
| Acronym | TUXIRA (Reference Number: 10400) |
| Duration | 01/10/2016 - 01/10/2019 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 5 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 23906 | TubaScan Limited | Coordinator | Netherlands |
| 23907 | Delta Diagnostics trading as Elucigene Diagnostics | Partner | United Kingdom |
| 23908 | Stichting VU-VUmc | Partner | Netherlands |